[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sale transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sale transaction in company stock. On May 8, 2026, he exercised stock options to acquire a total of 3,540 shares of common stock at an exercise price of $46.54 per share.
That same day, he executed open-market sales totaling 3,540 shares at prices ranging from approximately $78.00 to $79.31 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,212 shares of PTC Therapeutics common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,540 shares ($115K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Boulding Mark Elliott
Role
EXEC. VP AND CLO
Sold
3,540 shs ($280K)
Approx. gross sale proceeds
$280K
Approx. exercise cost
$165K
Approx. pre-tax spread
$115K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,740 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 800 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,740 | $46.54 | $128K |
| Sale | Common Stock | 840 | $78.23 | $66K |
| Sale | Common Stock | 1,900 | $79.31 | $151K |
| Exercise | Common Stock | 800 | $46.54 | $37K |
| Sale | Common Stock | 200 | $78.00 | $16K |
| Sale | Common Stock | 600 | $79.28 | $48K |
Holdings After Transaction:
Stock Option (Right to Buy) — 41,460 contracts (Direct);
Common Stock — 105,212 shares (Direct)
Footnotes (5)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.03 to $79.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.02 to $79.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Key Figures
Shares sold: 3,540 shares
Sale prices: $78.00–$79.31 per share
Options exercised: 3,540 shares
+3 more
6 metrics
Shares sold
3,540 shares
Open-market sales on May 8, 2026
Sale prices
$78.00–$79.31 per share
Weighted average price ranges for sales
Options exercised
3,540 shares
Common stock acquired via option exercise
Option exercise price
$46.54 per share
Exercise price for stock options
Shares held after transactions
105,212 shares
Direct common stock ownership post-transaction
Transaction date
May 8, 2026
Date of exercises and sales
Key Terms
Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title":"Stock Option (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description":"Exercise or conversion of derivative security"
open-market sale financial
"transaction_action":"open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
